BSE Pharma Sector Regulatory Filings — October 15, 2026

Board approved up to EUR 45Mn additional investment (aggregate EUR 50Mn) to acquire 70% of ACTx for ~EUR 48Mn in instalments, signalling a push into next-generation CAR-T oncology via a wholly owned Netherlands vehicle

FY26 ESG rating of 71 assigned independently by NSE Sustainability, a positive ESG data point disclosed alongside the acquisition news

FY26 ESG rating fell to 70 from 71, with one-point declines in both Social and Governance sub-scores, a modest governance-quality concern

Q2 FY27 (quarter ended 30 September 2026) results and a 1-hour earnings call are fixed for 30 October 2026 at 6:30 pm IST, creating a defined near-term re-rating window

Zydus Sunshine Lifesciences JV with Sunshine Healthcare signed a Sri Lanka BOI agreement on 13 October 2026 for a phased investment exceeding USD 20Mn on a ~4-acre Horana site, extending footprint into a supply-resilience market

Q2 FY27 results to be posted 4 November 2026 with an analyst call on 5 November 2026 at 3:00 PM IST, providing a scheduled checkpoint for hospital-sector sentiment

Transaction is structured as cash consideration paid in instalments with the Company's 100% ownership of the Netherlands vehicle unchanged, limiting dilution and keeping control with the parent

ACTx's paid-up share capital is only EUR 0.02Mn against EUR 50Mn authorised capital, and no target financials are disclosed, so valuation cannot be benchmarked against peers from these filings

EUR 48Mn for a 70% stake in a development-stage CAR-T company with no disclosed turnover or profit (target financials not disclosed) carries execution and valuation uncertainty

Aggregate Netherlands investment ceiling raised to EUR 50Mn, with the Netherlands subsidiary incorporated only on 13 August 2026 and nil turnover, meaning returns are unproven and fully deferred

Governance and Social sub-scores both declined one point, and the rating was assigned independently, so the company has no direct engagement to explain the drop

Commercial operations are not expected until 2028 and remain subject to timelines and regulatory approvals, leaving a multi-year gap before any earnings contribution

ACTx turnover, profitability and pipeline-stage detail are absent from the filings, limiting investor ability to assess the pre-revenue asset quality

Multiple notices (Apollo, Sun Pharma) contain no financial figures, so no period-over-period performance verification is possible from this batch and reliance falls on upcoming results

Acquiring 70% of a Belgian next-generation CAR-T developer with lead programs in non-Hodgkin lymphoma and small cell lung cancer offers exposure to high-value oncology cell therapy at an early stage

Positive FY26 ESG rating of 71 combined with an active R&D and niche-therapy strategy may support ESG-screened institutional inflows

Results and call on 30 October 2026 provide a scheduled event to reassess margin and specialty-portfolio trajectory ahead of the October-quarter print

Oral solid dosage manufacturing for the Sri Lankan market under BOI incentives can capture import-substitution demand and deepen South Asian market share

Results on 4 November 2026 with a call on 5 November offer a clear near-term read on hospital volumes and profitability for the quarter ended 30 September 2026

A one-point ESG decline is marginal, so restoration in the next rating cycle could be a low-cost narrative catalyst if governance and social scores are addressed

Instalment-based payment and subsidiary-level structuring allow capital to be staged against ACTx milestones, reducing upfront risk for the parent

Mankind's EUR 48Mn ACTx acquisition for CAR-T programs in non-Hodgkin lymphoma and small cell lung cancer signals Indian pharma moving beyond generics into advanced therapies, with implications for R&D budgets and partnering activity

Mankind (71) and Lupin (70) received FY26 ratings differing by one point with opposite directions (up and down), indicating governance and social scoring remains a differentiator among large-cap Indian pharma even among peers of similar size

Zydus's USD 20Mn+ Sri Lanka facility and Mankind's Netherlands vehicle both show Indian pharma committing capital abroad, either for local supply security or European R&D exposure

Sun Pharma (30 October), Apollo Hospitals (4-5 November) and related disclosures cluster into a compressed window, concentrating sector sentiment into a few weeks

Several filings (Apollo, Sun Pharma, Mankind's ACTx notice) omit target or period financials, so investors must rely on subsequent results rather than the notices themselves for quantitative validation

Results and 1-hour earnings call on 30 October 2026 at 6:30 pm IST, audio webcast and transcript to be posted at www.sunpharma.com; watch for specialty and US generics commentary

Results on 4 November 2026 with analyst/investor call on 5 November 2026 at 3:00 PM IST; watch for hospital occupancy and margin trends

Monitor the timing and tranches of the ~EUR 48Mn payment and any milestone disclosures from ACTx's non-Hodgkin lymphoma and small cell lung cancer programs

Track whether the EUR 50Mn aggregate ceiling is drawn down and whether the subsidiary reports first turnover or R&D spending

Watch for regulatory and timeline milestones following the 13 October 2026 BOI agreement toward 2028 commercial operations

Monitor Social and Governance sub-score actions ahead of the FY27 rating to see whether the one-point decline reverses

Track whether the 71 FY26 rating is maintained or improved in subsequent assessments given the newly announced international expansion